CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- FinancialsAltman Z-Score 2.38: grey zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.35%Below 5Y avg (0.75%)
Annual Rate
CNY 0.03Paid annual
Payout Ratio
167.6%High
Last Ex-Dividend
May 27, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.11BCNY313.60M · vs all stocks (USD)
Trailing P/E
210.50xvs Biotechnology peers
Revenue (TTM)
735.18MCNY109.19M · vs all stocks (USD)
Profit Margin
1.15%vs Biotechnology peers
Beta
-0.0100xvs all stocks
52-Week Change
-32.58%vs all stocks
Market Capitalization
2.11BCNY313.60M · vs all stocks (USD)
Enterprise Value
2.45BCNY363.33M · vs all stocks (USD)
Trailing P/E
210.50xvs Biotechnology peers
Forward P/E
10.53xvs Biotechnology peers
Price to Sales (TTM)
2.80xvs Biotechnology peers
Price to Book (MRQ)
1.57xvs Biotechnology peers
Enterprise to Revenue
3.33xvs Biotechnology peers
Enterprise to EBITDA
42.70xvs Biotechnology peers
Gross Margin
72.49%vs Biotechnology peers
Profit Margin
1.15%vs Biotechnology peers
Operating Margin
6.03%vs Biotechnology peers
Return on Assets (TTM)
0.76%vs Biotechnology peers
Return on Equity (TTM)
0.69%vs Biotechnology peers
Revenue (TTM)
735.18MCNY109.19M · vs all stocks (USD)
Revenue per Share (TTM)
3.12CNYUpdated Aug 20, 2026Quarterly Revenue Growth
-7.50%vs Biotechnology peers
Gross Profit (TTM)
524.52MCNY77.90M · vs all stocks (USD)
EBITDA (TTM)
69.36MCNY10.30M · vs all stocks (USD)
Net Income (TTM)
8.42MCNY1.25M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-16.50%vs Biotechnology peers
Operating Cash Flow (TTM)
111.37MCNY16.54M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
52.40MCNY7.78M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.0300CNYUpdated Aug 20, 2026Trailing Annual Dividend Yield
0.35%vs all stocks
5-Year Average Dividend Yield
0.75%vs all stocks
Payout Ratio
167.60%vs Biotechnology peers
Revenue
749.72MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
213.07MCNYFY2025 · Dec 31, 2025Gross Profit
536.65MCNYFY2025 · Dec 31, 2025Operating Income
30.12MCNY4.47M · vs all stocks (USD)
Pre-tax Income
9.77MCNYFY2025 · Dec 31, 2025Income Tax Expense
657.98KCNYFY2025 · Dec 31, 2025Net Income
9.11MCNYFY2025 · Dec 31, 2025EBIT
27.53MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
69.36MCNYFY2025 · Dec 31, 2025Research & Development
42.55MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
157.68MCNYFY2025 · Dec 31, 2025Other Operating Expenses
14.19MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
416.22KCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
17.76MCNYFY2025 · Dec 31, 2025Net Income from Continuing Operations
9.11MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
52.86MCNYFY2025 · Dec 31, 2025Free Cash Flow
3.40MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
173.72MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
9.11MCNYFY2025 · Dec 31, 2025Other Non-cash Items
23.49MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
49.95MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-29.69MCNYFY2025 · Dec 31, 2025Capital Expenditures
-49.45MCNYFY2025 · Dec 31, 2025Net Acquisitions
-2.99MCNYFY2025 · Dec 31, 2025Purchase of Investments
-55.00MCNYFY2025 · Dec 31, 2025Sale of Investments
15.01MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-92.43MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
532.75MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-421.63MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-41.42MCNYFY2025 · Dec 31, 2025Other Financing Charges
-5.44MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
64.25MCNYFY2025 · Dec 31, 2025Shares Outstanding
244.10MSharesUpdated Aug 20, 2026Float Shares
158.34MSharesUpdated Aug 20, 2026% Held by Insiders
32.83%vs all stocks
% Held by Institutions
2.15%vs all stocks
Total Cash (MRQ)
167.21MCNY24.83M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.7110CNYUpdated Aug 20, 2026Total Debt (MRQ)
632.34MCNY93.92M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.5020xvs Biotechnology peers
Current Ratio (MRQ)
1.34xvs Biotechnology peers
Book Value per Share (MRQ)
5.35CNYUpdated Aug 20, 2026Total Assets
2.12BCNY315.02M · vs all stocks (USD)
Total Current Assets
651.04MCNYFY2025 · Dec 31, 2025Total Liabilities
864.83MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.47BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
484.63MCNYFY2025 · Dec 31, 2025Total Current Liabilities
380.20MCNYFY2025 · Dec 31, 2025Cash
173.72MCNYFY2025 · Dec 31, 2025Cash Equivalents
2.65KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
173.72MCNYFY2025 · Dec 31, 2025Other Short-term Investments
96.87KCNYFY2025 · Dec 31, 2025Accounts Receivable
268.40MCNYFY2025 · Dec 31, 2025Inventory
172.11MCNYFY2025 · Dec 31, 2025Accounts Payable
68.59MCNYFY2025 · Dec 31, 2025Short-term Debt
242.65MCNYFY2025 · Dec 31, 2025Other Current Liabilities
2.43MCNYFY2025 · Dec 31, 2025Long-term Debt
426.25MCNYFY2025 · Dec 31, 2025Common Stock (Book)
244.10MCNYFY2025 · Dec 31, 2025Retained Earnings
555.99MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.26BCNY186.58M · vs all stocks (USD)
Treasury Stock
75.30MCNYFY2025 · Dec 31, 202552-Week Low
7.04CNYUpdated Aug 20, 202652-Week High
14.21CNYUpdated Aug 20, 202652-Week Change
-32.58%vs all stocks
Beta
-0.0100xvs all stocks
50-Day MA
7.83CNYUpdated Aug 20, 2026200-Day MA
9.57CNYUpdated Aug 20, 2026Avg 10-Day Volume
8.37MSharesUpdated Aug 20, 2026Avg 30-Day Volume
8.45MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
0.0400CNYUpdated Aug 20, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock valued?
Close Below 40W SMA With Profitability
The price sits below its 40-week average, on three profitable years and cash above profit.
Reads
Drawdown With FCF And Cash Backing
Well below its peak, with three years of positive free cash flow behind it.
Reads
Where is this company structurally exposed?
Down-Close Share With Multi-Year Earnings Decrease
Most weeks closed down this year, and earnings and gross profit fell over four.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.72Profit Margin: 0.01
Financial Health
Altman Z-Score 2.38: grey zoneSignificant
Altman Z-Score: 2.38
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Eledon Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Allgens Medical Technology Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Won Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Lavipharm S.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Animalcare Group Plc
Tier 1ProductionApproval-Gated PipelineRuleFlow
Medy-Tox Inc.
Tier 1ProductionApproval-Gated PipelineRule
Solara Active Pharma Sciences Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Santhera Pharmaceuticals Holding AG
Tier 1ProductionApproval-Gated PipelineRuleRisk
AP Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleInterface
Shin Poong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Winnebago Industries, Inc.
2 interpretationsDrawdown With FCF And Cash BackingClose Below 40W SMA With Profitability
Wingstop Inc.
2 interpretationsDrawdown With FCF And Cash BackingClose Below 40W SMA With Profitability
Builders FirstSource Inc.
3 interpretationsDrawdown With FCF And Cash BackingClose Below 40W SMA With ProfitabilityDown-Close Share With Multi-Year Earnings Decrease